头孢吡肟模型引导精准给药的群体药动学模型预测性能评估
该研究评估了InsightRX软件中两个头孢吡肟群体药动学模型在不同采样方案下的预测性能,以重症患者历史数据为参考。结果显示两个模型对清除率的预测误差可接受,但中央室分布容积的预测误差较大;不同模型和采样方案对达标率预测的一致性高,支持将MIPD用于头孢吡肟治疗药物监测。
要点
- 两个模型在所有采样方案下对清除率的MPE<±20%且MAPE<30%。
- 中央室分布容积的预测误差多数场景>±20%和>30%,排除体外支持患者后改善。
- 不同模型和采样方案预测≥70% fT>MIC(8/16mg/L)达标仅4例患者不一致。
核心结论
- 两个群体药动学模型及所有采样方案对头孢吡肟药动学参数和药效学暴露的预测可接受,适合用于MIPD进行TDM。
研究设计与样本
- 回顾性评估研究,使用以重症患者为主(部分接受体外支持)的历史头孢吡肟PK数据和个体贝叶斯估计作为参考标准。
- 评估InsightRX中两个群体PK模型(A和B)在四种采样方案下的预测性能。
主要发现
- 清除率的MPE和MAPE因模型和采样策略而异,但所有测试场景下两模型总体MPE<±20%、MAPE<30%;采样方案4的清除率MPE为-2.4%至4.4%。
- 中央室分布容积在多数测试场景下MPE>±20%且MAPE>30%;排除体外支持患者后,模型A的MPE/MAPE为3.7-4.8/23.3%-34.5%,模型B为-7.9-2.5/25.2%-29.6%。
- 使用各模型和采样方案预测≥70% fT>MIC(8/16mg/L)达标时,仅4例患者出现不一致。
关键数值与推荐
- 预测性能指标:中位预测误差(MPE)和中位绝对预测误差(MAPE)针对清除率(CL)和中央室分布容积(Vc)。
- 药效学目标:≥70%时间游离药物浓度高于MIC(fT>MIC,8/16mg/L)。
- 采样方案:仅谷浓度、仅中点浓度、谷+中点、峰+中点+谷。
临床怎么用
- 临床可选用InsightRX中任一模型及上述采样方案进行头孢吡肟MIPD,尤其关注清除率的预测可靠性。
- 对接受体外支持的患者,中央室分布容积预测误差可能增大,需谨慎解读。
- 峰+中点+谷采样方案对清除率预测误差较低(MPE -2.4%至4.4%)。
局限性
- 研究基于历史数据,主要为重症患者,部分接受体外支持,可能限制普遍性。
- 中央室分布容积预测误差在多数场景下较大,可能影响剂量优化精度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Model-informed precision dosing (MIPD) is a promising tool used to ensure therapeutic antimicrobial concentrations. Model selection and sampling strategy might lead to different pharmacokinetic (PK) parameter estimates. Herein, we assess the predictive performance for cefepime PK in two models implemented within the InsightRX software using differing sampling approaches. METHODS: Historic cefepime PK data and individual Bayesian estimates in predominantly critically ill patients, some of whom had extracorporeal support, served as the reference standard. Two population PK models (A; B) were evaluated using four sampling scenarios: (i) trough only, (ii) midpoint only, (iii) trough + midpoint, and (iv) peak + midpoint + trough. The median prediction error (MPE) and median absolute prediction error (MAPE) were calculated for clearance (CL) and volume of central compartment (Vc). Predicted categorical achievement of ≥70% time that the free drug concentration was greater than the minimum inhibitory concentration [fT>MIC(8/16mg/L)] was compared. RESULTS: MAPE and MPE for CL and Vc resulted in variability that was dependent on model and sampling strategy. Both models' overall MPE and MAPE for CL were <±20 and <30% for all tested scenarios, respectively, with a low MPE of -2.4% to 4.4% on CL for sampling scenario 4. For Vc, MPE and MAPE were >±20 and >30% for the majority of test scenarios across both models, respectively. When excluding patients with extracorporeal support, MPE/MAPE for Vc decreased to 3.7-4.8/23.3%-34.5% and -7.9-2.5/25.2%-29.6% for model A and B, respectively. Using each model and sampling scheme, only four patients had discordant predicted achievement of ≥70% fT>MIC(8/16mg/L). CONCLUSIONS: These two population PK models and all sampling scenarios demonstrated acceptable prediction of cefepime PK parameters and pharmacodynamic exposures; therefore, they demonstrated suitability for utilizing MIPD for cefepime therapeutic drug monitoring.
引用
- König C, Kuti JL, Fratoni AJ, et al. Predictive performance of population pharmacokinetic models in InsightRX® for model-informed precision dosing for Cefepime. Pharmacotherapy. 2025. PMID: 40353524. doi:10.1002/phar.70029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。